Comparative evaluation and preference of MixPro^® versus Mix2Vial^® reconstitution devices among people with haemophilia and caregivers

1 Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D. Establishing the prevalence and prevalence at birth of hemophilia in males. Ann Intern Med 2019; 171(8): 540–6. doi: 10.7326/m19-1208%m31499529. IorioA StonebrakerJS ChambostH MakrisM CoffinD Establishing the prevalence and prevalence at birth of hemophilia in males Ann Intern Med 2019 171 8 540 6 10.7326/m19-1208%m31499529 Open DOISearch in Google Scholar

2 Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 S6 1 158 10.1111/hae.14046 32744769 Open DOISearch in Google Scholar

3 Munn J, Khair K, Scott A, et al. Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro^®). J Haem Pract 2016; 3(1): 33–8. doi: 10.17225/jhp00073 MunnJ KhairK ScottA Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro^®) J Haem Pract 2016 3 1 33 8 10.17225/jhp00073 Open DOISearch in Google Scholar

4 Poonnoose P, Carneiro JDA, Cruickshank AL, et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study. Haemophilia 2017; 23(4): doi: 538–46. 10.1111/hae.13242. PoonnooseP CarneiroJDA CruickshankAL Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study Haemophilia 2017 23 4 538 46 10.1111/hae.13242 28574179 Open DOISearch in Google Scholar

5 van den Berg HM. From treatment to prevention of bleeds: what more evidence do we need? Haemophilia 2017; 23(4): 494–6. doi: 10.1111/hae.13256. van den BergHM From treatment to prevention of bleeds: what more evidence do we need? Haemophilia 2017 23 4 494 6 10.1111/hae.13256 28544023 Open DOISearch in Google Scholar

6 Centers for Disease Control and Prevention. Community Counts Registry Report – Males with Hemophilia 2014–2017. 16. Treatment / Treatment Regimen and Hemophilia Severity; 2020. Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-males/treatment.html (accessed 28 July 2022). Centers for Disease Control and Prevention Community Counts Registry Report – Males with Hemophilia 2014–2017. 16 Treatment / Treatment Regimen and Hemophilia Severity; 2020 Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-males/treatment.html (accessed 28 July 2022). Search in Google Scholar

7 Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10(2): 165–8. doi: 10.2450/2012.0147-11. MakrisM Prophylaxis in haemophilia should be life-long Blood Transfus 2012 10 2 165 8 10.2450/2012.0147-11 332077422337280 Open DOISearch in Google Scholar

8 Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49–56. doi: 10.2147/jbm.S43734. SaxenaK Barriers and perceived limitations to early treatment of hemophilia J Blood Med 2013 4 49 56 10.2147/jbm.S43734 Open DOISearch in Google Scholar

9 Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8(4): 292–6. doi: 10.2450/2010.0067-10. FranchiniM Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better Blood Transfus 2010 8 4 292 6 10.2450/2010.0067-10 295749620967172 Open DOISearch in Google Scholar

10 Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 2002; 1–9. doi: 10.1182/asheducation-2002.1.1. MannucciPM Hemophilia and related bleeding disorders: a story of dismay and success Hematology Am Soc Hematol Educ Program 2002 1 9 10.1182/asheducation-2002.1.1 12446416 Open DOISearch in Google Scholar

11 United States Government. Federal Register. Determination of regulatory review period for purposes of patent extension: antihemophilic factor concentrate (recombinant). Washington DC, USA; 1993. United States Government Federal Register. Determination of regulatory review period for purposes of patent extension: antihemophilic factor concentrate (recombinant) Washington DC, USA 1993 Search in Google Scholar

12 Pfizer; Wyeth Pharmaceuticals LLC. BeneFIX^®: Highlights of prescribing information. Revised 4/2021. Available from: https://www.fda.gov/media/73556/download (accessed 28 July 2022). Pfizer Wyeth Pharmaceuticals LLC BeneFIX^®: Highlights of prescribing information. Revised 4/2021. Available from: https://www.fda.gov/media/73556/download (accessed 28 July 2022). Search in Google Scholar

13 Musso R, Santoro R, Coppola A, et al. Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010; 3: 203–8. doi: 10.2147/ijgm.s12096. MussoR SantoroR CoppolaA Patient preference for needleless factor VIII reconstitution device: the Italian experience Int J Gen Med 2010 3 203 8 10.2147/ijgm.s12096 291553220689694 Open DOISearch in Google Scholar

14 Cimino E, Linari S, Malerba M, et al. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: 10.2147/PPA.S64709. CiminoE LinariS MalerbaM Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries Patient Prefer Adherence 2014 8 1713 20 10.2147/PPA.S64709 427029925525348 Open DOISearch in Google Scholar

15 Ingle RG, Fang W-J. Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. Int J Pharm 2021; 597: 120314. doi: 10.1016/j.ijpharm.2021.120314. IngleRG FangW-J Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system Int J Pharm 2021 597 120314 10.1016/j.ijpharm.2021.120314 33540011 Open DOISearch in Google Scholar

16 Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of a pre-filled diluent syringe (MixPro) among patient/carer users and nurses. J Haem Pract 2018; 5(1): 12–23. doi: 10.17225/jhp00106. PollardD KhairK PercierC WongY ShoemarkR Evaluation of a pre-filled diluent syringe (MixPro) among patient/carer users and nurses J Haem Pract 2018 5 1 12 23 10.17225/jhp00106 Open DOISearch in Google Scholar

17 Novo Nordisk. NovoSeven RT coagulation factor VIIa (recombinant). 2019. Available from: https://www.novosevenrtpro.com/resources/patient-support/patient-education/mixpro-brochure.html (accessed 28 July 2022). Novo Nordisk NovoSeven RT coagulation factor VIIa (recombinant) 2019 Available from: https://www.novosevenrtpro.com/resources/patient-support/patient-education/mixpro-brochure.html (accessed 28 July 2022). Search in Google Scholar

18 West Pharmaceutical Services. Mix2Vial. 2017. Available from: https://www.westpharma.com/-/media/WestPharma/Files/Products/Mix2Vial-Information-Sheet.pdf (accessed 28 July 2022). West Pharmaceutical Services Mix2Vial 2017 Available from: https://www.westpharma.com/-/media/WestPharma/Files/Products/Mix2Vial-Information-Sheet.pdf (accessed 28 July 2022). Search in Google Scholar

19 Octapharma USA Inc. WILATE: Highlights of prescribing information. Revised September 2019. Available from https://www.fda.gov/media/77812/download (accessed 28 July 2022). Octapharma USA Inc WILATE: Highlights of prescribing information Revised September 2019. Available from https://www.fda.gov/media/77812/download (accessed 28 July 2022). Search in Google Scholar

20 Grifols Biologicals LLC. Alphanate: Highlights of prescribing information. Revised 06/2018. Available from: https://www.grifols.com/documents/260038/65508/ft-alphanate-us-en/a9f2f9c9-05eb-4fac-a7d3-5f091c198cff (accessed 28 July 2022). Grifols Biologicals LLC Alphanate: Highlights of prescribing information Revised 06/2018. Available from: https://www.grifols.com/documents/260038/65508/ft-alphanate-us-en/a9f2f9c9-05eb-4fac-a7d3-5f091c198cff (accessed 28 July 2022). Search in Google Scholar

21 Grifols Biologicals LLC. Coagulation factor IX (human); AlphaNine^® SD. Revised July 2013. Available from: https://www.grifols.com/documents/260038/89417/ft_alphanine_malasia_EN/a1bc830a-346a-474f-8bcc-4faca132c559 (accessed 29 July 2022). Grifols Biologicals LLC Coagulation factor IX (human) AlphaNine^® SD. Revised July 2013. Available from: https://www.grifols.com/documents/260038/89417/ft_alphanine_malasia_EN/a1bc830a-346a-474f-8bcc-4faca132c559 (accessed 29 July 2022). Search in Google Scholar

22 CSL Behring. Idelvion: Summary of product characteristics. 2016; last updated 15/12/2021. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 28 July 2022). CSL Behring Idelvion: Summary of product characteristics 2016 last updated 15/12/2021. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 28 July 2022). Search in Google Scholar

23 CSL Behring. Hexilate: Highlights of prescribing information. Revised 5/2016. Available from: https://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf (accessed 28 July 2022). CSL Behring Hexilate: Highlights of prescribing information Revised 5/2016. Available from: https://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf (accessed 28 July 2022). Search in Google Scholar

24 Novo Nordisk. Novoeight: antihemophilic factor (recombinant): Highlights of prescribing information. 07/2020. Available from: https://www.novo-pi.com/novoeight.pdf (accessed 28 July 2022). Novo Nordisk Novoeight: antihemophilic factor (recombinant): Highlights of prescribing information 07/2020. Available from: https://www.novo-pi.com/novoeight.pdf (accessed 28 July 2022). Search in Google Scholar

25 Novo Nordisk. Refixia: Summary of product characteristics. 2017; last updated 07/03/2022. Available from: https://www.ema.europa.eu/en/documents/product-information/refixiaepar-product-information_en.pdf (accessed 28 July 2022). Novo Nordisk Refixia: Summary of product characteristics 2017 last updated 07/03/2022. Available from: https://www.ema.europa.eu/en/documents/product-information/refixiaepar-product-information_en.pdf (accessed 28 July 2022). Search in Google Scholar

26 Genentech, Inc. HEMLIBRA^® (emicizumab): Highlights of prescribing information. Revised: 11/2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed 28 July 2022). Genentech, Inc HEMLIBRA^® (emicizumab): Highlights of prescribing information Revised: 11/2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed 28 July 2022). Search in Google Scholar

27 Bradley-Terry model. Encyclopedia of Mathematics. Revision 24 March 2012. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=22181 (accessed 28 July 2022). Bradley-Terry model. Encyclopedia of Mathematics Revision 24 March 2012. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=22181 (accessed 28 July 2022). Search in Google Scholar

28 Bradley-Terry model. Encyclopedia of Mathematics. Revision 30 May 2020. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=46143 (accessed 28 July 2022). Bradley-Terry model. Encyclopedia of Mathematics Revision 30 May 2020. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=46143 (accessed 28 July 2022). Search in Google Scholar

29 Novo Nordisk. Rebinyn: Highlights of prescribing information. Revised 06/2017. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---REBINYN.pdf (accessed 28 July 2022). Novo Nordisk Rebinyn: Highlights of prescribing information Revised 06/2017. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---REBINYN.pdf (accessed 28 July 2022). Search in Google Scholar